Patient Information
Your one place for clear, patient-relevant information, trusted advice and dependable ongoing support. Please feel free to contact us if there is anything you’re unsure on – we’re here to help.
Introduction
UNDERSTANDING
NON-SMOKING LUNG CANCERS
If you have been diagnosed with lung cancer and have never smoked, it cigarettes is the biggest cause of lung cancer, never smokers can get lung cancer too.
Ruth realised that there wasn’t enough information for patients diagnosed with non-smoking lung cancers and that there was a need for more collaboration and research into these types of lung cancers. We hope that the information provided below will empower to you to better understand your diagnosis, the disease and as well as food for thought on questions you could be asking your specialists.
ANYONE WITH LUNGS
CAN GET LUNG CANCER
Non-smoking lung cancers & what you should know about them
We hope that the information provided below will help you you a better understanding of the possible drivers behind non-smoking lung cancers; and most importantly, offer some guidance on the questions you could ask your oncologist so that you can be given the best possible course of treatment – no matter what stage your cancer is.
With huge thanks to Professor Sanjay Popat, Consultant Thoracic Medical Oncologist at The Royal Marsden Hospital NHS Foundation Trust for helping us put this (hopefully) simple and comprehensive guide together.
We hope it empowers you to ask the right questions, allowing you to understand this complex disease a bit better and ensuring you receive the most effective treatment.
We will use two terms to describe those who don’t smoke, and are diagnose with lung cancer: never smoking lung cancers and non smokng lung cancers.
Both mean the same thing.
Did you know?
Anyone who has smoked less than 75 cigarettes in their lifetime is considered a non-smoker.
”Understanding cancer & medical terminology can be very confusing. We hope to simplify some of the basic lung cancer terminology here, helping you to understand your diagnosis, enabling you to ask important questions along the way. In case it helps, you can find a downloadable document below on which you can highlight the information you have picked up, and make notes of missing information or add your questions for your next oncologist visit."
Deepa DoshiHead of Mission Services
Diagnosis FAQs
NON-SMOKING LUNG CANCERS.
QUESTIONS YOU MAY HAVE OR COULD BE ASKING:
What are non-smoking lung cancers?
LUNG CANCER TYPES, SUB-TYPES & STAGING
Smokers and non- or never-smokers tend to develop different types of cancer as a result of genetic mutations or abnormalities. A non-smoker is someone who does not currently smoke but may have smoked around 75 cigarettes at some point in their life. Never-smokers are people who have never smoked or smoked fewer than 75 cigarettes in their lifetime.
Our focus, and the Ruth Strauss Foundation’s mission, centres around lung cancers not caused by smoking.
Non-smoking lung cancer tumours differ from smoking-related lung cancers in their origins and the genetic drivers behind the disease.
To determine whether you have lung cancer, your medical team will carry out tests such as a chest X-ray, CT scan or biopsy. These tests help identify the type and subtype of lung cancer you have, as well as the stage of your cancer. This information enables your oncologist to plan the most appropriate treatment for you.
WHAT TYPE OF LUNG CANCER DO I HAVE?
TYPES OF LUNG CANCER
Cancer that begins in the lungs is called primary lung cancer. When cancer cells have spread to a patient’s lungs from a cancer that started somewhere else in the body, it’s called secondary lung cancer. This guide is for patient’s diagnosed with a primary lung cancer.
THERE ARE TWO TYPES OF LUNG CANCERS:
NON-SMALL CELL LUNG CANCER (NSCLC)
80% of lung cancer diagnoses are called non-small cell lung cancer. In most cases, non-smokers develop non-small cell lung cancer. In the ‘sub-type’ section we will therefore focus on this type of non-smoking lung cancer.
SMALL CELL LUNG CANCER
20% of lung cancer diagnoses are called small cell lung cancer and these are extremely rare in non-smokers.
Did you know?
These names, small cell and non-small cell lung cancer, were adopted in the 1960s when oncologists (doctors who diagnose and treat cancer) needed to know which form of lung cancer they were dealing with for treatment purposes. The naming non-small celllung cancer derived initially from how these tumour cells looked under the microscope – not small vs small cell lung cancer cells.
Types of Cancer
WHAT SUB-TYPE OF LUNG CANCER DO I HAVE?
There are many sub-types of non-small cell lung cancer, but scientists have identified two major sub-types.
With 80% of non-smoking lung cancers being non-small cell lung cancers, our focus below will be on the two key sub-types of this cancer type: Adenocarcinoma and Squamous Carcinoma. About 50% to 60% of lung cancers found in people who never smoked are adenocarcinomas. About 10% to 20% are squamous cell carcinomas.
ADENOCARCINOMA
An adenocarcinoma is a type of cancerous tumour that starts in cells that release substances, like mucus. They are usually found in the outer parts of the lung.
SQUAMOUS CARCINOMA
A squamous carcinoma is a type of cancerous tumour that forms in the thin, flat cells lining the inside of the lungs.
Did you know?
Anyone who has smoked less than 75 cigarettes in their lifetime is considered a non-smoker. We will use two terms to describe those who don’t smoke, and are diagnosed with lung cancer: never smoking lung cancers and non smoking lung cancers. Both meaning the same.
Stages of Cancer
WHAT STAGE IS MY CANCER?
Cancer staging is the process of determining the extent to which a cancer has developed (the tumour’s size) and spread.
Simply put, a patient’s cancer stage is determined by how much cancer you have in your body. Below we have broken it down into simple terms, but more information is available here.
DETERMINING THE CANCER STAGE HELPS AN ONCOLOGIST DECIDE ON THE BEST COURSE OF TREATMENT, WHICH CAN INCLUDE:
- Surgery
- Radiation
- Drugs (e.g. chemotherapy, immune therapy etc)
- Targeted therapies
”In an ideal world, you are given all the information about your cancer in one go and there is a clear plan of action. Unfortunately, it’s often not so straight forward. To start with, receiving the news that you have cancer will come as an incredible shock, which means that you probably won’t absorb all the details that were shared with you. A second consultation will allow you to ask further questions. In addition, once a cancer diagnosis is made, further steps need to be taken to find out more about your cancer. For non-smoking lung cancers it is vital that a biopsy is taken and send off for molecular testing.”
Professor Sanjay PopatRSF Scientific Advisor
Where To Go From Here
What’s Next?
Finding out the driver behind your cancer
Step 1 of diagnosis is finding out your type, sub-type and stage of your cancer.
Step 2 is finding out what the driver is behind your cancer. If this can be determined, a more targeted and tailored treatment plan can be put together for you. All of this information (type, sub-type and driver) can, in most cases, be found by pathologists examining the tumour.
The driver behind non-smoking lung cancers is in most cases a gene mutation or alteration. In simple terms, a change or malfunction in your DNAs building blocks. It is not always possible to find the driver but through comprehensive molecular testing (study of your biopsy), specialists have a better chance of finding out.
QUESTIONS YOU COULD BE ASKING
MOLECULAR PROFILING AND WHY IS THIS SO IMPORTANT
A human body is made up of cells. Each cell contains a complete organism to develop, survive and reproduce. Genes are small sections of DNA. Some genes act as instructions to make molecules called proteins. Proteins make up body structures like organs and tissue, as well as control chemical reactions and carry signals between cells. If a cell’s DNA is mutated (a change in a DNA sequence), an abnormal protein may be produced, which can disrupt the body’s usual processes and lead to a disease such as cancer.
Due to major advances in the mapping of the human genome, we now know what human genes look like and can therefore identify any abnormalities or changes to our genes. It’s these gene alterations which help a cancer grow and spread. Knowing what gene alteration a tumour carries, allows oncologists to better determine what drugs a patient can benefit from. The process of analysing a patient’s genes is called molecular profiling.
Note: it is not the person’s genes (i.e. genetics) that are abnormal but the cancer’s genes that are abnormal. We don’t know what triggers the cancer genes to become abnormal in a never-smoker. Finding causes for these gene alterations is an active area of research.
Your cancer’s genetic profile & why this impacts treatment Understanding the genetic profile of the cancer helps oncologists work out what the right treatment for the patient is.
Molecular profiling has become fundamental not only to inform on a patient’s tumour diagnosis and prognosis(outlook) but most importantly, this unique information can help your oncologist personalise your treatment plan by considering which treatments your cancer is likely to respond to.
IN NON-SMOKING LUNG CANCERS A NUMBER OF GENE MUTATIONS HAVE BEEN IDENTIFIED. THE LIST IS GROWING AND WE WILL DO OUR BEST TO KEEP THIS UPDATED:
ALK REARRANGEMENT
ALK is the name of a protein with the role of telling cells to stop growing. If you have been diagnosed with ALK+ lung cancer, this gene and another gene are broken off and have rearranged, preventing it from its function to stop cells from growing.
ROS1 FUSION
ROS1 is the name of a protein that functions in a similar way as the ALK gene. If you have been diagnosed with ROS1+ lung cancer, this gene has fused with a nearby gene. This “drives” abnormal cell growth.
EGFR MUTATION
EGFR is the name of a protein that instructs the growth and division of cells. EGFR+ lung cancer means that this gene has mutated (changed), causing the cancer cells to grow and spread.
RET FUSION
The RET gene provides instructions for producing a protein that is involved in signalling within cells, and appears essential for the normal development of several kinds of nerve cells. If you have been diagnosed withRET fusion lung cancer, this gene “drives” abnormal cell growth.
BRAF MUTATION
The BRAF gene provides instructions for making a protein that helps transmit chemical signals from outside the cell to the cell’s nucleus (its core). BRAF mutations affect the growth, division, specific functions, movement and the self-destruction of cells.
KRAS MUTATION
The KRAS gene provides instructions for making a protein which relays signals from outside the cell to the cell’s nucleus (its core). When mutated, KRAS mutations can affect cell division, cell differentiation, and the self-destruction of cells, with the potential to cause normal cells to become cancerous.
Did you know?
A biopsy is when a small piece of the tumour is removed for analysis, to be able to:
1. Confirm the cancer type (read more above)
2. Identify the abnormal gene behind the cancer
Comprehensive genomic testing can determine whether for example cancer tissue.
This vital information will allow an oncologist to set a patient up on the most appropriate & effective treatment course.
MOLECULAR PROFILING
– or “tumour genomic profiling”—is a form of testing that classifies tumours based on their genetic make-up to help diagnose and treat cancer. Using a blood test or biopsy, this form of testing examines the genes of cancer cells, looking for mutations (abnormal changes to the build of cells) that have been acquired by these cells.
DIAGNOSED WITH LUNG CANCER BUT NO MOLECULAR ABNORMALITY DETECTED?
If you have been diagnosed with lung cancer but no molecular abnormality has been detected, then we advise you to:
- Request any left-over cancer biopsy material to be sent to an NHS Genomic Laboratory Hub (GLH) for comprehensive testing of all eight genes (find out more in the section below about UK’s GLHs)
- If there is no specimen left from the original biopsy, ask for another biopsy to be done when it’s safe to do so, and request for this to be sent off to an NHS GLH for comprehensive testing of all eight genes
”The genomic abnormality behind your cancer may not be druggable, even if you find out what it is, but at least you know what you are dealing with and a best course of treatment can be prescribed.”
Professor Sanjay PopatRSF Scientific Advisor
UP TO JUST A FEW YEARS AGO, SCIENTISTS WERE ONLY LOOKING OUT FOR ABOUT THREE GENETIC ABNORMALITIES IN PATIENT’S BIOPSY SAMPLES.
In 2007 testing started on the EGFR gene. In 2010 this was followed by Gene testing has evolved significantly over the past 10 years, with tests initially happening in local hospitals or labs. However, in 2018 NHS England decided to centralise all genomic testing into seven Genomic Laboratory Hubs (GLHs) in England, and a Genomic Medicine Service (GMS) was put in place from later 2019, with the aim of providing consistent and fair access to genomic testing. The GMS is a nationally founded laboratory service for cancer patients in England, ensuring equitable access for clinicians and patients across England. There are similar set-ups within laboratories in Scotland, Wales and Northern Ireland.
Very recently NHS England set up a Genomic Medicine Service (GMS) with the aim of providing consistent and fair access to genomic testing. The GMS will provide a nationally funded laboratory service for cancer patients in England, ensuring equitable access for clinicians and patients across England.
Every patient with a lung cancer diagnosis is meant to have their specimen sent for state-of-the-art comprehensive molecular testing. Here the NHS is funding the analysis of eight genes, using what is called Next Generation Sequencing Tests.
Comprehensive molecular testing is THE most important thing your doctor can do to find out what the molecular abnormality is that is driving your cancer. It is your right to get your cancer tested for these eight genes. Finding the driver behind your cancer will allow your oncologist to give you the best possible treatment.
NLH Networks
THE 7 GENOMIC LABORATORY HUB (GLH) NETWORKS AND THEIR LEADING TRUSTS IN ENGLAND.
The Future
AFTER DIAGNOSIS
What does treatment for non-smoking lung cancers look like?
Below we share some general guidance on non-smoking lung cancer lung cancers in the various stages are treated. However, each patient’s cancer presentation is unique, and a treatment plan will be determined accordingly.
In general, Stage I and II non-smoking lung cancer is treated with surgery to cut out the cancer.
The surgery may need to be followed up with chemotherapy to minimise the risk of relapse (i.e. the cancer returning). And depending on the molecular profile of your cancer, the oncologist may also want to give targeted treatment (often taken as a tablet) to again minimise the risk of the cancer coming back.
For example, in case the abnormal gene detected is the EGFR gene, you might be recommended an EGFR inhibitor tablet, called Osimertinib. Whereas if your non-smoking lung cancer shows the genetically altered ALK gene, there are trials ongoing at the moment to see whether an ALK tablet, Alectinib, is useful after surgery.
We are working on sharing more information on non-smoking lung cancer clinical trials with you in the near future.
Stage III non-smoking lung cancer is a complex disease, with many different ‘sub-types’.
If you have been diagnosed with stage IV non-smoking lung cancer, unless it’s really urgent, don’t start with treatment without knowing what the molecular profile is. The way in which the NHS drug funding works, could mean that if you start a treatment, you might be committed to quite a long series of treatment. This could mean that, for example, if you start on treatment “A”, this will only allow you to continue onto treatment “B” or “C”.
However, if you didn’t start in the “right way”, sometimes this can impact your treatment options in the future.
NOTE: Molecular profiling might not necessarily help you in an immediate way (i.e., there may not be a targeted treatment available), but it might help you be considered for other experimental research or clinical trials that are ongoing.
TREATMENT OFTEN COMPRISES A COMBINATION OF DRUGS AND THERAPIES, ALSO REFERRED TO AS MODALITIES. THE USE OF DIFFERENT MODALITIES IS CALLED A MULTI-MODALITY APPROACH.
Here are some of the more common treatment combinations used in stage
1. Chemotherapy + Radiotherapy (called chemoradiation)
2. Chemotheraphy + Radiotherapy + Surgery
Often an oncologist will prescribe one year of immunotherapy post the above treatment course, to minimise the risk of a relapse.
However, there is some data that challenges whether the immunotherapies are effective in patients with certain genetic alternations, such as EGFR mutations. Again – knowing your cancer’s molecular profile allows you to discuss with your oncologist whether this is the right treatment pathway for you.
As mentioned earlier, comprehensive molecular profiling also allows a patient to be considered for research trials, with the potential to be considered for new treatments as well.
When your cancer started in your lung and has travelled to other parts of the lung or other parts of the body, this is usually treated with drug treatments alone.
In a patient diagnosed with Stage IV, understanding the molecular profile of the cancer is extremely important as it can help your oncologist work out which one of the above treatments is right for you. This is the case even for lung cancer in patients with a smoking history.
Patients with a non-smoking lung cancer have a much higher probability of having a genetic alteration in their cancer, compared to patients who have smoked in their life-time.
”For never-smoker patients with stage 4 disease I always say we have got to wait for the molecular results to come through. Unless it’s an emergency. In which case we start treatment with chemotherapy. Waiting for the molecular test results to come through will really help us work out what the right treatment for you is and there’s a very high likelihood that you will need molecular targeted therapy (TKI)."
Professor Sanjay PopatRSF Scientific Advisor
Resource Download
Need to share this information with a Friend or Family member?
Please find our information document available for download below.
